U.S., Feb. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07432386) titled 'Methotrexate Versus Apremilast for Pruritus in Psoriasis' on Feb. 19.
Brief Summary: This randomized controlled trial aims to compare the efficacy of Methotrexate versus Apremilast in reducing pruritus and improving quality of life in patients with psoriasis. Eighty patients aged 20 to 60 years with psoriasis involving more than 8% body surface area and associated pruritus will be enrolled and randomly assigned into two groups. Group A will receive oral Apremilast titrated to 30 mg twice daily, while Group B will receive oral Methotrexate 10 mg once weekly for 8 weeks. The primary outcome will be change in Dermatology Life Quality I...